J&J is already a player in the market for drugs to treat resistant MDD with nasal spray antidepressant Spravato (esketamine ... cancer biotech IDRx and its KIT inhibitor for gastrointestinal ...

An antidepressant containing a form of the drug ketamine has been added to the Pharmaceutical Benefits Scheme (PBS), making ...

patients will still need to pay for the professional clinic visits required for supervised administration of the nasal spray. "While I think [listing Spravato on the PBS] is a useful step ...

A new nasal spray that uses a form of ketamine to treat difficult-to-treat depression will soon become more accessible to tens of thousands of Australians. Spravato, which contains esketamine ...

This week, the US Food and Drug Administration expanded its approval of Spravato, an antidepressant nasal spray. The drug, made by Johnson & Johnson, is now cleared for use as the only standalone ...

The study is published in Nature Communications. During the early COVID-19 pandemic, this platform enabled the rapid development of a nasal spray vaccine in collaboration with mainland China's ...

Scientists have pioneered an influenza virus vector-based nasal spray vaccine platform and developed a nasal spray H5N1 avian influenza vaccine. During the early COVID-19 pandemic, this platform ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

Spray it ain’t so! It’s bad enough you’re brushing your teeth all wrong — now it turns out you’ve also been abusing your nasal spray. “I was yesterday years old when I learned there ...